Tangible Shareholders Equity: The value shareholders equity less intangible assets.
Galmed Pharmaceuticals Ltd. (GLMD) had Tangible Shareholders Equity of $16.88M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-1.10M |
|
-- |
|
-- |
|
$1.26M |
|
$-1.26M |
|
$0.16M |
|
$-1.10M |
|
$-1.10M |
|
$-1.10M |
|
$-1.10M |
|
$-1.10M |
|
$-1.10M |
|
$-1.26M |
|
$-1.23M |
|
1.78M |
|
1.78M |
|
$-0.62 |
|
$-0.62 |
|
| Balance Sheet Financials | |
$16.30M |
|
-- |
|
$2.39M |
|
$18.68M |
|
$1.81M |
|
-- |
|
-- |
|
$1.81M |
|
$16.88M |
|
|
Tangible Shareholders Equity |
$16.88M |
$16.88M |
|
2.26M |
|
| Cash Flow Statement Financials | |
$-1.17M |
|
$-0.23M |
|
$1.51M |
|
$4.77M |
|
$4.89M |
|
$0.12M |
|
$0.10M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
9.02 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-1.17M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-6.54% |
|
-6.54% |
|
-5.91% |
|
-6.54% |
|
$7.47 |
|
$-0.66 |
|
$-0.66 |
|